• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cure.低剂量率前列腺近距离放射疗法（LDR-PB）采用术后前列腺特异抗原（PSA）值来定义治疗是否成功。
BJUI Compass. 2020 Oct 19;2(1):9-10. doi: 10.1002/bco2.49. eCollection 2021 Jan.
2
Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer.前列腺特异性抗原（PSA）升高的时间可区分前列腺癌高剂量率（HDR）和低剂量率（LDR）近距离放射治疗后的PSA反弹。
J Contemp Brachytherapy. 2018 Feb;10(1):1-9. doi: 10.5114/jcb.2018.73786. Epub 2018 Feb 26.
3
A biochemical definition of cure after brachytherapy for prostate cancer.前列腺癌近距离放射治疗后的生化治愈定义。
Radiother Oncol. 2020 Aug;149:64-69. doi: 10.1016/j.radonc.2020.04.038. Epub 2020 Apr 27.
4
Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.比较接受低剂量率近距离放射治疗和强度调制放射治疗的前列腺癌患者在最后一次随访时的 PSA 值。
BMC Cancer. 2017 Aug 25;17(1):573. doi: 10.1186/s12885-017-3565-1.
5
Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer.最小剂量接受 90%的尿道百分比（%UD90）是接受低剂量率近距离放射治疗（LDR-近距离放射治疗）治疗前列腺癌患者 PSA 反弹的最显著预测指标。
BMC Urol. 2012 Sep 14;12:28. doi: 10.1186/1471-2490-12-28.
6
Defining Biochemical Cure After Low Dose Rate Prostate Brachytherapy: External Validation of 4-year Prostate-specific Antigen Nadir as a Predictor of 10- and 15-year Disease-free Survival.低剂量率前列腺近距离治疗后生化治愈的定义：4 年前列腺特异性抗原最低点作为 10 年和 15 年无病生存预测因子的外部验证。
Clin Oncol (R Coll Radiol). 2022 Jan;34(1):42-49. doi: 10.1016/j.clon.2021.11.009. Epub 2021 Nov 28.
7
Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.根治性放疗后复发性前列腺癌的挽救性近距离放疗：低剂量率与高剂量率近距离放疗的比较及前列腺特异性抗原倍增时间的重要性
Brachytherapy. 2017 Nov-Dec;16(6):1091-1098. doi: 10.1016/j.brachy.2017.07.013. Epub 2017 Aug 21.
8
The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.前列腺癌风险评估 (CAPRA) 评分可预测接受外照射放疗 (EBRT) 剂量递增或低剂量率 (LDR) 近距离放疗的中危前列腺癌的生化复发。
BJU Int. 2014 Dec;114(6):865-71. doi: 10.1111/bju.12587. Epub 2014 Mar 14.
9
Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.低剂量率近距离放射治疗局部前列腺癌在疾病复发高风险男性中的应用。
BJU Int. 2018 Oct;122(4):610-617. doi: 10.1111/bju.14223. Epub 2018 May 8.
10
Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival.低剂量率前列腺近距离放射治疗后 4 至 5 年内的前列腺特异性抗原是无病生存的强有力预测指标。
Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):87-93. doi: 10.1016/j.ijrobp.2013.10.010.

引用本文的文献

1
The great escape: A tale of the visiting professor's Artful Dodge.成功逃脱：一位客座教授巧妙回避的故事。
BJUI Compass. 2021 Jan 26;2(1):3-6. doi: 10.1002/bco2.66. eCollection 2021 Jan.
2
Prospective Evaluation of Prostate and Organs at Risk Segmentation Software for MRI-based Prostate Radiation Therapy.基于MRI的前列腺放射治疗中前列腺及危及器官分割软件的前瞻性评估
Radiol Artif Intell. 2022 Jan 26;4(2):e210151. doi: 10.1148/ryai.210151. eCollection 2022 Mar.

本文引用的文献

1
A biochemical definition of cure after brachytherapy for prostate cancer.前列腺癌近距离放射治疗后的生化治愈定义。
Radiother Oncol. 2020 Aug;149:64-69. doi: 10.1016/j.radonc.2020.04.038. Epub 2020 Apr 27.
2
Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.在ASCENDE-RT随机对照试验中，对于接受根治性放射治疗的中高危前列腺癌患者，使用手术前列腺特异性抗原阈值>0.2 ng/mL来定义生化失败。
Brachytherapy. 2018 Nov-Dec;17(6):837-844. doi: 10.1016/j.brachy.2018.08.008. Epub 2018 Sep 21.
3
Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.低剂量率近距离放射治疗局部前列腺癌在疾病复发高风险男性中的应用。
BJU Int. 2018 Oct;122(4):610-617. doi: 10.1111/bju.14223. Epub 2018 May 8.
4
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.雄激素抑制联合选择性淋巴结及剂量递增放射治疗（ASCENDE-RT试验）：一项针对高风险和中风险前列腺癌的随机试验的生存终点分析，该试验比较了低剂量率近距离放疗增敏与剂量递增外照射增敏。
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026. Epub 2016 Nov 24.

Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cure.

作者信息

Uribe Jennifer, Uribe-Lewis Santiago, Khaksar Sara, Perna Carla, Mikropoulos Christos, Otter Sophie, Laing Robert, Langley Stephen

机构信息

The Stokes Centre for Urology Royal Surrey Hospital NHS Foundation Trust Guildford UK.

出版信息

BJUI Compass. 2020 Oct 19;2(1):9-10. doi: 10.1002/bco2.49. eCollection 2021 Jan.

DOI:10.1002/bco2.49
PMID:35474662
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8988796/
Abstract
摘要